clinical trial · NCT03872921
norUrsodeoxycholic Acid vs Placebo in PSC
Dr. Falk Pharma GmbH·phase3·active not recruiting·n = 303
Primary Sclerosing CholangitisnorUrsodeoxycholic Acid
brief summary
Double-blind, randomized, multi-center, placebo-controlled, comparative, phase III trial. The study will be conducted with two treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with either 1500 mg/d norursodeoxycholic acid capsules or placebo capsules for the treatment of Primary Sclerosing Cholangitis.
started
Feb 8, 2018
primary completion
Jan 1, 2025
completion
Jun 1, 2026
last updated
Aug 6, 2024
official title
Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol